November 28, 2024
TOPLINE: Biosimilars demonstrate comparable drug survival and safety with adalimumab among new users, but patients switching from Humira (the originator product) to biosimilars had a 35% […]
November 27, 2024
TOPLINE: Merkel cell polyomavirus (MCPyV) and ambient ultraviolet radiation (UVR) exposure account for most Merkel cell carcinoma (MCC) cases in the United States. METHODOLOGY: Researchers evaluated […]
November 27, 2024
The drug survival for adalimumab is significantly higher than that of infliximab in pediatric patients with hidradenitis suppurativa (HS), results from a small single-center study showed. […]
November 27, 2024
“For too long, the management of psoriasis and other immune-mediated inflammatory diseases has suffered from an acceptance that improvement rather than cure is good enough. Our […]
November 26, 2024
TOPLINE: Lichen planus (LP) affects an estimated 0.15% of US adults, and more than half of patients do not receive treatment within a year of diagnosis […]
November 25, 2024
Recently published consensus guidelines for low-dose oral minoxidil (LDOM) treatment of hair loss provide best-practice recommendations in areas ranging from pretreatment considerations and counseling to patient […]
November 22, 2024
LAS VEGAS — When patients with rosacea consult Julie C. Harper, MD, about persistent facial erythema, she often recommends brimonidine 0.33% gel or oxymetazoline 1% cream. […]
November 22, 2024
Nearly every medication comes with side effects, and in cancer therapies, they can be severe. Clinicians must often weigh the benefits of treatment against potential adverse […]
November 20, 2024
The US Food and Drug Administration has approved bimekizumab, a humanized interleukin (IL)-17A and IL-17F antagonist, for the treatment of adults with moderate to severe hidradenitis […]